A Study of Nemtabrutinib Versus Comparator
Phase 3
1,200
about 8.7 years
18+
41 sites in AL, AZ, CA +19
What this study is about
This trial is testing nemtabrutinib compared to investigator's choice of ibrutinib or acalabrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if nemtabrutinib is as effective as these other medications, and whether it helps patients live longer without their cancer getting worse.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Acalabrutinib
- 2.Take Ibrutinib
- 3.Take Nemtabrutinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
acalabrutinib, ibrutinib, kinase inhibitor
oral (Oral Capsule), oral (Oral Tablet)
Primary: Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR), Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR
Secondary: Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience One or More Adverse Events (AEs), Overall Survival (OS)
Oncology